WASHINGTON--(ML Strategies, as Senior Vice President, Life Sciences. Dr. Hammang brings an extensive background in science and technology policy development, strengthening the consulting firm’s ability to provide strategic public affairs and policy advisory services to a range of life sciences, pharmaceutical and health care clients. ML Strategies is the government relations consulting affiliate of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C..)--Dr. Joseph Paul Hammang, a former senior executive at Pfizer Inc., has joined the Washington, D.C. office of
“Joe brings an outstanding life sciences background and significant experience helping companies and organizations to shape public policy on Capitol Hill.”
For the last decade, Dr. Hammang has played a key role in the development of internal and external policies for numerous critical issues facing the global biopharmaceutical industry on behalf of Pfizer Inc., where he served most recently as Senior Director, Worldwide Science Policy. Leading a team of scientific professionals and serving as liaison with industry trade organizations, his experience covered complex areas including: personalized medicine, stem cells and regenerative medicine, ethnic diversity in clinical medicine, conflicts of interest and the industry’s role in public-private partnerships, among others.
“Today’s regulatory environment requires companies in these industries to stay abreast of what is happening in Washington and to ensure that their interests are well-represented,” said Susan W. Berson, Managing Member of Mintz Levin’s Washington, D.C. office and a member of the firm’s Health Law Section. “Joe brings an outstanding life sciences background and significant experience helping companies and organizations to shape public policy on Capitol Hill.”
“With a proven track record in science and technology policy development, Joe has significant experience translating complex scientific concepts into clear policy and public affairs positions and communications,” added Stephen P. Tocco, President and CEO of ML Strategies. “His expertise is a great complement to our existing offerings and we are delighted to welcome him to our team of senior professionals.”
Prior to joining Pfizer Inc., Mr. Hammang served as a senior science and technology official on the Rhode Island Economic Policy Council and Rhode Island Economic Development Corporation. Earlier in his career he was with Cyto Therapeutics and the Bristol-Myers Squibb Pharmaceutical Research Institute. He earned a doctorate degree in the area of neuroscience from the University of Wisconsin.